Photocure ASA

Photocure announces resignation of Chief Operating Officer

Oslo, Norway, 26 May 2016: Photocure ASA announces today that its Chief

Operating Officer, Kathleen Deardorff, has resigned effective 1 June 2016 to

pursue other career opportunities. Ms Deardorff has been with Photocure since

2011, serving as Chief Operating Officer during her entire tenure.

"During her five years at Photocure, Kathleen has made significant contributions

to the company. She has been an important part of our management team and we

wish her all the best in her future endeavours," says Kjetil Hestdal, M.D.,

Ph.D., President and CEO, Photocure ASA.

During the transition process and search for a suitable full-time successor is

successfully fulfilled, Photocure will allocate the position's key operational

duties to the current management team.

For further information, please contact:

Photocure

President & CEO Kjetil Hestdal

Tel: + 47 913 19 535

CFO Erik Dahl

Tel: +47 450 55 000

Notes to editors

About Photocure ASA

Photocure, headquartered in Oslo Norway, is a specialty pharmaceutical company

and world leader in photodynamic technology. Based on our unique proprietary

Photocure Technology(TM) platform, Photocure develops and commercializes highly

selective and effective solutions within disease areas with high unmet medical

need, such as bladder cancer, HPV and precancerous cervical lesions, colorectal

cancer and skin conditions. Our aim is to provide solutions which can improve

health outcomes for patients worldwide. Photocure is listed on the Oslo Stock

Exchange (OSE: PHO). Information about Photocure is available at

www.photocure.com

This information is subject of the disclosure requirements acc. to §5-12 vphl

(Norwegian Securities Trading Act)

[HUG#2015829]

AI Terminal